On this page
Study tools
Exam tags
Write your answer
Saved on this device. No marking — you are the marker.
Stem
A candidate is asked to manage a classic presentation of Chronic Coronary Syndrome in an exam setting. Use precise definitions, scores, doses, and decision thresholds.
Core knowledge (model answer backbone)
Chronic coronary syndrome (CCS) is the modern umbrella term replacing "stable angina" for the long-term presentations of coronary artery disease. Defined by the 2019 ESC Guidelines as the spectrum of clinical presentations driven by chronic, often predictable, myocardial ischaemia typically precipitated by exertion or emotional stress and relieved by rest or sublingual nitrates. Anatomically it is the consequence of fixed or dynamic epicardial coronary stenosis (atherosclerotic plaque with intact fibrous cap), microvascular dysfunction, or vasospasm. The classic presentation is substernal chest discomfort provoked by exertion and resolving within minutes of rest or nitroglycerin, graded I to IV on the Canadian Cardiovascular Society scale. Atypical presentations are common in women, diabetics and the elderly. Investigations progress from resting ECG and echocardiography through functional imaging (stress echocardiography, stress perfusion MRI, SPECT) or anatomical imaging (CT coronary angiography) to invasive coronary angiography with physiology (FFR, iFR) — the 2019 ESC recommends an imaging test rather than exercise ECG as the initial diagnostic test wherever possible. Management combines lifestyle modification, disease-modifying secondary prevention (antiplatelet therapy, a statin, an ACE inhibitor where indicated), stepwise anti-anginal therapy, and revascularisation reserved for refractory symptoms or high-risk anatomy.[1]
Red flags
- Sudden accelerating or crescendo angina pattern over days to weeks - signals plaque instability and imminent acute coronary syndrome; needs urgent cardiology review, anti-ischaemic intensification, and consideration of inpatient angiography
- Rest angina (CCS class IV) lasting over 20 minutes, with dynamic ECG changes, or with new left ventricular dysfunction - high-risk unstable presentation; treat on the NSTE-ACS pathway with an early invasive strategy guided by risk
- Angina with new heart failure signs (orthopnoea, S3 gallop, pulmonary crackles) - extensive ischaemia or previous silent infarction with adverse remodelling; urgent imaging (echo), risk stratification, and revascularisation consideration
- Angina with syncope or presyncope - severe ischaemia, arrhythmia, or left main / multivessel disease; admit for telemetry, exclude arrhythmic cause, consider early angiography
High-yield structure examiners expect
Cover: Overview & Definition, Classification, Epidemiology & Risk Factors, Pathophysiology, Clinical Presentation, Differential Diagnosis.
Key doses / thresholds (from topic teaching)
- Antiplatelet: aspirin 75 to 100 mg once daily (COMPASS used 100 mg once daily), or clopidogrel 75 mg once daily as the trial-proven alternative[6][4]
- Statin: atorvastatin 80 mg is offered to people with established cardiovascular disease whatever their cholesterol level (NICE NG238); the 2019 ESC goal is to cut LDL-C by at least 50 percent from baseline and to below 1.4 mmol/L (55 mg/dL)[8][1]
- Calcium-channel blocker: amlodipine 5 mg titrated to 10 mg once daily; a beta-blocker OR a calcium-channel blocker is the recommended first anti-anginal[1]
- Ivabradine 5 mg twice daily for 4 weeks, then 7.5 mg twice daily (10 mg twice daily was the upper arm in the comparative trial), sinus rhythm only; it matched atenolol 50 then 100 mg daily for exercise tolerance[5][1]
- Long-acting nitrate: dose asymmetrically to preserve a nitrate-free or nitrate-low interval of about 8 to 10 hours; after a PDE5 inhibitor, withhold nitrates for 24 hours (sildenafil, vardenafil) to 48 hours (tadalafil)[2]
- Intensified secondary prevention in high-risk chronic coronary disease: rivaroxaban 2.5 mg twice daily plus aspirin (COMPASS) and colchicine 0.5 mg once daily (LoDoCo2)[6][7]
- Physiology thresholds for revascularisation: FFR 0.80 or below (FAME 2 randomisation threshold) and iFR 0.89 or below[3][1]
Questions
a) Define the condition and give the most important classification or severity framework used in exams. (3 marks)
- Clear one-line definition matching standard teaching.
- Named classification / stages / types with discriminating features.
- One sentence on why classification changes management.
b) Outline pathophysiology in a mechanism chain that explains the main clinical features. (3 marks)
- Initiating insult → intermediate pathway → end-organ effect.
- Link at least two symptoms/signs to mechanism.
- Mention one complication pathway (e.g. shock, perforation, herniation, arrhythmia).
c) List discriminating clinical features and bedside assessment. (3 marks)
- Classic presentation plus one atypical group (elderly, pregnancy, child, immunocompromised).
- Named signs/manoeuvres if relevant.
- What must never be missed on exam/bedside (pregnancy test, airway, glucose, etc.).
d) Investigations with thresholds and one named score if applicable. (3 marks)
- First-line tests and what positive findings mean.
- Gold-standard or definitive investigation when needed.
- Score components reproduced exactly if a named score is standard for this topic.
e) Immediate resuscitation and definitive management with doses where standard. (3 marks)
- ABC / time-critical steps first.
- First-line drug(s) with agent + dose + route (or procedure steps).
- Escalation triggers (theatre, ICU, thrombolysis window, antidote, etc.).
- Disposition and safety-netting.
Marking tips
Full marks require specificity (numbers, names, doses) not generic "give antibiotics/fluids." Regional practice (ICMR / NICE / AHA) may be cited as alternative where relevant.
References8ShowHide
- [1]Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020.PMID 31504439
- [2]Task Force Members, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal, 2013.PMID 23996286
- [3]De Bruyne B, Fearon WF, Pijls NH, et al. (FAME 2 Trial Investigators) Fractional flow reserve-guided PCI for stable coronary artery disease. New England Journal of Medicine, 2014.PMID 25176289
- [4]CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996.PMID 8918275
- [5]Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. European Heart Journal, 2005.PMID 16214830
- [6]Eikelboom JW, Connolly SJ, Bosch J, et al. (COMPASS Investigators) Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine, 2017.PMID 28844192
- [7]Nidorf SM, Fiolet ATL, Mosterd A, et al. (LoDoCo2 Trial) Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine, 2020.PMID 32865380
- [8]National Institute for Health and Care Excellence (NICE) Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238), recommendation 1.7.2. NICE guideline NG238, 2023.Source